Editor: What To Know
- “Paul is a highly respected and talented leader within the medical technology industry, and his experience working with both large, global organizations and start-ups provides him with a unique perspective on strategy and innovation,”.
- Edwards announced in May the appointment of Ramona Sequeira to the board, and that Martha Marsh, a board member since 2015, would assume the role of lead independent director.
- Board, and we are confident that his breadth of experience within companies and on boards will enable him to be an immediate contributor, offering valuable insight to Edwards.
July 15, 2020
Paul A. LaViolette has been appointed to Edwards Lifesciences Corporation’s board of directors.
Paul A. LaViolette has 40 years of experience in global medical technology, operating leadership and investing, serving in executive-level roles at companies including Boston Scientific Corp. and C.R. Bard Inc.
LaViolette is currently managing partner and chief operating officer of SV Health Investors LLC, a specialist healthcare fund management company. He also oversees its medical device investments.
“Paul is a highly respected and talented leader within the medical technology industry, and his experience working with both large, global organizations and start-ups provides him with a unique perspective on strategy and innovation,” said Michael A. Mussallem, Edwards’ chairman and CEO. “We are very pleased to welcome Paul to Edwards’ board, and we are confident that his breadth of experience within companies and on boards will enable him to be an immediate contributor, offering valuable insight to Edwards.”
Edwards announced in May the appointment of Ramona Sequeira to the board, and that Martha Marsh, a board member since 2015, would assume the role of lead independent director. With the appointment of LaViolette, Edwards’ board increases to nine directors.
